Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response

Simple item page
dc.contributor.authorRotman, Y.
dc.contributor.authorBorg, B. B.
dc.contributor.authorSoza, A.
dc.contributor.authorFeld, J. J.
dc.contributor.authorModi, A. A.
dc.contributor.authorLoomba, R.
dc.contributor.authorLutchman, G.
dc.contributor.authorRivera, E.
dc.contributor.authorDoo, E.
dc.contributor.authorGhany, M. G.
dc.contributor.authorHeller, T.
dc.contributor.authorNeumann, A. U.
dc.contributor.authorLiang, T. J.
dc.contributor.authorHoofnagle, J. H.
dc.date.accessioned2024-01-10T12:06:23Z
dc.date.available2024-01-10T12:06:23Z
dc.date.issued2010
dc.description.abstractP>Background
dc.description.abstractChronic infection with hepatitis C, genotype 2/3, responds better than other genotypes to peginterferon and ribavirin treatment. We hypothesized that a lower dose of peginterferon would be as effective, but less toxic than standard doses.
dc.description.abstractAim
dc.description.abstractTo test the hypothesis that a lower dose of peginterferon would be as effective as, but less toxic than, standard doses.
dc.description.abstractMethods
dc.description.abstractA total of 30 patients were treated with low-dose peginterferon alfa-2a (90 mu g/week) and 27 patients with standard doses (180 mu g/week) for 24 weeks in combination with 800 mg/day of ribavirin. Patients who failed treatment were offered 48 weeks of standard-dose treatment. Viral and serum inducible protein 10 (IP-10) levels were measured and early viral kinetic parameters were calculated.
dc.description.abstractResults
dc.description.abstractSustained virological response was achieved in 68% of the low-dose and 87% of the standard-dose patients (per protocol, P = 0.79 for non-inferiority). Re-treatment was successful in all patients who tolerated full dose and duration. The standard-dose group had greater first-phase declines of viral levels and faster time to negativity. The second-phase slope was not dose-dependent. IP-10 induction was significantly greater with the standard dose. Although fatigue and general feeling during treatment were worse for standard dose, haematological toxicity and depression did not differ between groups.
dc.description.abstractConclusion
dc.description.abstractA lower dose of peginterferon is associated with some symptomatic benefit, but the response is not equivalent to standard dosing.
dc.description.funderNational Institute of Diabetes and Digestive and Kidney Diseases
dc.description.funderNational Institutes of Health
dc.description.funderNATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
dc.fechaingreso.objetodigital2024-05-07
dc.format.extent10 páginas
dc.fuente.origenWOS
dc.identifier.doi10.1111/j.1365-2036.2010.04263.x
dc.identifier.issn0269-2813
dc.identifier.pubmedidMEDLINE:20163377
dc.identifier.urihttps://doi.org/10.1111/j.1365-2036.2010.04263.x
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/76154
dc.identifier.wosidWOS:000276356900010
dc.information.autorucMedicina;Soza A;S/I;461
dc.issue.numero9
dc.language.isoen
dc.nota.accesocontenido parcial
dc.pagina.final1027
dc.pagina.inicio1018
dc.publisherWILEY-BLACKWELL PUBLISHING, INC
dc.revistaALIMENTARY PHARMACOLOGY & THERAPEUTICS
dc.rightsacceso restringido
dc.subjectRANDOMIZED CONTROLLED-TRIAL
dc.subjectPLUS RIBAVIRIN
dc.subjectINITIAL TREATMENT
dc.subjectGENE-EXPRESSION
dc.subjectPEGYLATED INTERFERON
dc.subjectANTIVIRAL THERAPY
dc.subjectINFECTED PATIENTS
dc.subjectHCV GENOTYPE-2
dc.subjectCOMBINATION
dc.subjectVIRUS
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleLow- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response
dc.typeartículo
dc.volumen31
sipa.codpersvinculados461
sipa.indexWOS
sipa.indexScopus
sipa.trazabilidadCarga SIPA;09-01-2024
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3 efficacy, tolerability, viral kinetics and cytokine response.pdf
Size:
3.3 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas